Skip to main content
SpringerLink
Log in

Staging in Multiple Myeloma

  • Chapter
Myeloma Therapy

Part of the book series: Contemporary Hematology ((CH))

  • 574 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Carbone, P.P., L.E. Kellerhouse,and E.A. Gehan, Plasmacytic myeloma. A study of the relationship of survival to various clinical manifestations and anomalous protein type in 112 patients. Am J Med, 1967. 42(6): pp. 937–48.

    Article  PubMed  CAS  Google Scholar 

  2. Dawson, A. A and D. Ogston, Factors influencing the prognosis in myelomatosis Postgrad Med J, 1971. 47(552): pp. 635–8.

    Article  PubMed  CAS  Google Scholar 

  3. Report on the first myelomatosis trial. I. Analysis of presenting features of prognostic importance. Br J Haematol, 1973. 24(1): pp. 123–39.

    Article  Google Scholar 

  4. Bergsagel, D.E., P.J. Migliore, and K.M. Griffith, Myeloma proteins and the clinical response to melphalan therapy. Science, 1965. 148: pp. 376–7.

    Article  CAS  Google Scholar 

  5. Correlation of abnormal immunoglobulin with clinical features of myeloma. Arch Intern Med, 1975. 135(1): pp. 46–52.

    Google Scholar 

  6. Alexanian, R., et al., Prognostic factors in multiple myeloma. Cancer, 1975. 36(4): pp. 1192–201.

    Article  PubMed  CAS  Google Scholar 

  7. Durie, B.G. and S.E. Salmon, A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer, 1975. 36(3): pp. 842–54.

    Article  PubMed  CAS  Google Scholar 

  8. Bataille, R., B.G. Durie, and J. Grenier, Serum beta2 microglobulin and survival duration in multiple myeloma: a simple reliable marker for staging. Br J Haematol, 1983. 55(3): pp. 439–47.

    Article  PubMed  CAS  Google Scholar 

  9. Gobbi, P.G., et al., A plea to overcome the concept of staging and related inadequacy in multiple myeloma. Eur J Haematol, 1991. 46(3): pp. 177–81.

    Article  PubMed  CAS  Google Scholar 

  10. Merlini, G., P.G. Gobbi, and E. Ascari, The Merlini, Waldenstrom, Jayakar staging system revisited. Eur J Haematol Suppl, 1989. 51: pp. 105–10.

    PubMed  CAS  Google Scholar 

  11. Bataille, R., et al., Prognostic factors and staging in multiple myeloma: A reap-praisal. J Clin Oncol, 1986. 4(1): pp. 80–7.

    PubMed  CAS  Google Scholar 

  12. Jacobson, J.L., et al., A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience. Br J Haematol, 2003. 122(3): pp. 441–50.

    Article  PubMed  Google Scholar 

  13. Greipp, P.R., et al., International Staging System for multiple myeloma. J Clin Oncol, 2005. 23(15): pp 3412–20

    Article  PubMed  Google Scholar 

  14. Krejci, M., et al., Prognostic factors for survival after autologous transplantation: A single centre experience in 133 multiple myeloma patients. Bone Marrow Transplant, 2005. 35(2): pp. 159–64.

    Article  PubMed  CAS  Google Scholar 

  15. Bergsagel, P.L., et al., Cyclin D dysregulation: An early and unifying pathogenic event in multiple myeloma. Blood, 2005. 106(1): pp. 296–303.

    Article  PubMed  CAS  Google Scholar 

  16. Bergsagel, P.L. and W.M. Kuehl, Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol, 2005. 23(26): pp. 6333–8.

    Article  PubMed  CAS  Google Scholar 

  17. Durie, B.G., The role of anatomic and functional staging in myeloma: Description of Durie/Salmon plus staging system. Eur J Cancer, 2006. 42(11): pp. 1539–43.

    Article  PubMed  Google Scholar 

  18. Walker, R., et al., Magnetic resonance imaging in multiple myeloma: Diagnostic and clinical implications. J Clin Oncol, 2007. 25(9): pp. 1121–8.

    Article  PubMed  Google Scholar 

  19. Ghanem, N., et al., Whole–body MRI in the detection of bone marrow infitteration in patients with plasma cell neoplasms in comparison to the radiological skeletal survey. Eur Radiol, 2006. 16(5): pp. 1005–14.

    Article  PubMed  Google Scholar 

  20. Zamagni, E., et al., A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica, 2007. 92(1): pp. 50–5.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA

    Leonard T. Heffner

Authors
  1. Leonard T. Heffner
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Winship Cancer Institute, Emory University, B3307 Clifton Road, Atlanta, GA, 30322, USA

    Sagar Lonial MD

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Heffner, L.T. (2008). Staging in Multiple Myeloma. In: Lonial, S. (eds) Myeloma Therapy. Contemporary Hematology. Humana Press. https://doi.org/10.1007/978-1-59745-564-0_1

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-564-0_1

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-934115-82-4

  • Online ISBN: 978-1-59745-564-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation